Gf Fund Management Co. Ltd. T Scan Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.26 Trillion
- Q1 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,218 shares of TCRX stock, worth $1,887. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,218
Previous 1,031
18.14%
Holding current value
$1,887
Previous $3.13 Million
46.36%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TCRX
# of Institutions
89Shares Held
40.9MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$8.3 Million6.28% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$7.75 Million0.71% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$6.92 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$5.43 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$4.63 Million0.34% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $29.3M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...